Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft standard CEI-MS-13: Development and validation of a… — submissions

The 13 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-093/2
Series
Public comment period
Version
1.0
Published
04 Jul 2026
Last reviewed
04 Jul 2026
Next review
04 Jul 2027
Identifier
10.71829/cei.cp.93
Certainty
Not rated
Cycle
2026 Q3
Window
04 Jul 2026 – 15 Aug 2026
Status
Open
Submissions
13

§2Submissions and responses

13 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Xiomara Fairweather-Duru, PhD (Analytical Chemistry) Patient advocacy organisation
DRAFT-STABILITY-IN/006 received 08 Jul 2026

The same concept is given three different names in one document

The draft refers to the same quantity as a response rate, a responder proportion and a categorical outcome in different sections. The respondent, who works in health-technology assessment, states that a reader cannot tell whether the three refer to one thing or to three.

The respondent proposes that the glossary term be used at every occurrence and that the glossary entry be linked at first use in each section rather than only at first use in the document.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted18 Sep 2026

The secretariat accepts this submission. The variation was stylistic and its cost to the reader exceeds any benefit.

A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.

Dr Adaeze Dunmore-Ekpo, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-STABILITY-IN/009 received 12 Jul 2026

The limitations section states what the method cannot do but not what a reader will wrongly conclude

The limitations section is accurate and abstract. The respondent states that the misreadings this standard should prevent are specific and predictable, and that naming them would be more use than a general statement of scope.

The respondent proposes that the limitations section list the specific inferences a conformant result does not support.

Declared interest. Has received honoraria for educational lectures from a marketing-authorisation holder of a compound named in the draft, within the preceding three years.
Secretariat responseAccepted02 Sep 2026

The secretariat accepts this submission. A limitation stated abstractly is a limitation a reader will not apply to the case in front of them.

The limitations section now lists the specific conclusions a conformant determination does not support, each stated as a sentence a reader could otherwise have written, and the list is placed before the references rather than in an annex.

Dr Nikolai Yeovil-Bakare, PhD (Chemistry), MRSC University department of pharmacy practice
DRAFT-STABILITY-IN/011 received 13 Jul 2026

References should carry a persistent identifier for every cited source

Several references in the draft carry a journal, a year and a volume but no persistent identifier. The respondent, who works in a library setting, states that retrieval of such a reference is materially slower and that identifiers should be supplied throughout.

The respondent asks in the alternative that where an identifier exists but is not carried, the omission be explained rather than left as a gap the reader must interpret.

Declared interest. Employed by a health technology assessment body that has issued guidance on a compound named in the draft.
Secretariat responseAccepted in part24 Aug 2026

The secretariat accepts the second limb of this submission and declines the first. Identifiers are supplied wherever the Institute holds one. Where the Institute does not hold an identifier it will not supply one, because a reconstructed identifier that resolves to the wrong record is a worse defect than an absent one.

Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.

Xenia Nyquist-Obiora, MPharm, MRPharmS Academic nephrology unit
DRAFT-STABILITY-IN/003 received 15 Jul 2026

The document should state what a reader ought to do

The draft assesses evidence and stops. The respondent, a practising clinician, states that a reader arriving at the document with a decision to make is left to convert an assessment into an action without help, and proposes that each document close with a recommendation.

The respondent argues that other evidence bodies issue recommendations and that declining to do so transfers the difficult part of the work to the reader.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNot accepted03 Sep 2026

The secretariat does not accept this submission, and records that the point is a reasonable one rather than a misunderstanding.

The Institute assesses evidence and does not issue recommendations, because a recommendation embeds values and a resource context that the Institute does not hold and cannot state. That constitutional limit is published on the methodology page and is not varied by consultation. The submission remains published in full.

Leonhard Achterberg, PhD (Pharmaceutics) Endocrine surgery service
DRAFT-STABILITY-IN/008 received 15 Jul 2026

The document set should be published in translation

The respondent notes that the assessments concern compounds supplied internationally and that publishing only in English restricts access to the assessment to readers who work in it.

The respondent proposes machine translation of the document set as an interim measure, with human review of the certainty language.

Declared interest. No financial interest. Has published a systematic review reaching a different conclusion from the draft, which the respondent declares as a non-financial interest.
Secretariat responseNot accepted16 Sep 2026

The secretariat does not accept this submission, and records that the underlying point is sound and that the proposed remedy is the difficulty.

A translation whose certainty language has drifted is a different assessment carrying the Institute's name, and the Institute cannot review translations it does not have the capacity to review. The documents remain in English. The submission is published in full because the access problem it identifies is real and unresolved.

Dr Wilhelmina Erlingsson, RN, MSc (Advanced Practice) Sleep and respiratory medicine service
DRAFT-STABILITY-IN/010 received 17 Jul 2026

Nothing requires a laboratory to demonstrate ongoing performance

The respondent states that suitability criteria assessed within a run demonstrate that the run worked and not that the laboratory performs consistently over time.

The respondent proposes participation in a proficiency scheme as a condition of conformance.

Declared interest. Employed by a university department that has received unrestricted research funding from a manufacturer of a compound in the class under assessment. The respondent had no role in that funding.
Secretariat responseAccepted in part16 Sep 2026

The secretariat accepts this submission in part. A trend requirement on system suitability data is added. Proficiency scheme participation is not made a condition of conformance, for the same reason competence requirements are not.

The standard now requires that system suitability results be trended across runs and that a determination report whether the trend was within the laboratory's stated limits, which places the demonstration inside the document the Institute can read.

Dr Evander Whitmarsh-Obi, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-STABILITY-IN/012 received 20 Jul 2026

The standard should state a pass limit

The respondent states that a standard which reports a figure without a limit leaves the reader without a criterion, and that suppliers will set their own.

The respondent proposes a universal acceptance limit for the determination.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseNot accepted26 Aug 2026

The secretariat does not accept this submission. An appropriate limit depends on the compound, the presentation and the intended route, none of which the standard fixes.

The standard states performance and reports the figure as determined. Setting a universal limit would attach a pass or fail to materials whose acceptable ranges genuinely differ, which would be a stronger claim than the Institute can support. The submission remains published in full and the point is recorded in the limitations.

Dr Jozef Brandvold-Achterberg, PhD (Pharmacoepidemiology) Senior Lecturer in Pharmacoepidemiology
DRAFT-STABILITY-IN/013 received 21 Jul 2026

The document is unreadable without specialist training

The respondent, a trustee of a patient organisation, states that the draft is written for a reader who already understands certainty grading, and that the people most affected by the subject matter will not reach the assessment at all.

The respondent proposes a plain-language summary at the head of every document, written to the same standard of accuracy as the document itself and not as a promotional abstract.

Declared interest. Has received travel support to attend a scientific meeting from a manufacturer of a compound named in the draft.
Secretariat responseAccepted in part22 Aug 2026

The secretariat accepts this submission in part. A plain-language summary is added. The proposal that it replace the technical abstract is declined, because the abstract is the part of the document other assessors read and cite.

Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.

Dr Stellan Cholmondeley-Ade, MD, MSc Community pharmacy practice, doctoral candidate
DRAFT-STABILITY-IN/005 received 22 Jul 2026

The standard should require documented operator competence

The respondent states that the determination described requires judgement, particularly at the integration step, and that a competence requirement would improve consistency more than any change to the criteria.

The respondent proposes that conformance be conditional on documented operator training.

Declared interest. No interest to declare. The respondent is a graduate student and states that the submission forms no part of any assessed work.
Secretariat responseNot accepted29 Aug 2026

The secretariat does not accept this submission. Operator competence is a quality-system matter governed by accreditation requirements the Institute does not administer and cannot verify.

The standard states performance and remains silent on competence. Where judgement affects the result, as at the integration step, the standard requires the judgement to be recorded rather than the operator to be qualified, which is the part the Institute can check from a report. The submission remains published in full.

Dr Ndidi Ravensworth-Ilunga, MD, MSc (Clinical Trials) Clinical Trials Unit, academic
DRAFT-STABILITY-IN/007 received 01 Aug 2026

The draft prescribes a procedure where it should state performance

Several clauses specify a gradient, a column chemistry and a temperature. The respondent states that fixing these prevents a laboratory from using a validated equivalent, and that the Institute settled on stating performance when it scoped the series.

The respondent proposes that the prescriptive clauses be converted into performance requirements with the prescribed conditions retained as a worked example.

Declared interest. Employed by a national competent authority. This submission is made in a personal capacity and does not represent the position of that authority.
Secretariat responseAccepted03 Sep 2026

The secretariat accepts this submission. The draft departed from the position settled when the series was scoped, and the departure was not deliberate.

The prescriptive clauses are converted to performance requirements, the specific conditions are retained as a worked example clearly labelled as one, and a laboratory using a different validated procedure that meets the stated performance reports a conformant determination.

Nkechi Larsson-Ekwueme, MSc, CChem Academic sports-medicine and anti-doping laboratory
DRAFT-STABILITY-IN/002 received 02 Aug 2026

Declared interests should appear on the document rather than on a separate page

The draft links to a central conflicts register. The respondent argues that a reader assessing whether to rely on a particular document should not have to leave it to find out who assessed it and what they declared.

The respondent proposes that the interests of every named contributor to a document be printed on that document.

Declared interest. Holds a patent relating to a delivery technology referenced in the draft.
Secretariat responseNoted, no amendment02 Sep 2026

The secretariat notes this submission and records that the draft already provides for it, which the respondent could reasonably have missed because the provision sits in an appendix.

Every document carries the declared interests of its named contributors in its front matter, and the central register exists so that a reader can see a person across all documents rather than one at a time. No amendment arises; the provision has been moved from the appendix into the body of the methodology document so that it is findable.

Vittoria Quintanilha, MSc (Epidemiology) Academic clinical pharmacology unit · industry submission
DRAFT-STABILITY-IN/001 received 06 Aug 2026

The document should not describe uses outside the approved indication

The submission is made on behalf of a marketing-authorisation holder. It states that the draft describes uses of the compound that fall outside the approved indication, that such uses are not supported by the sponsor, and that describing them may be read as legitimising them.

The sponsor asks that the sections concerned be removed, or in the alternative that they carry a prominent statement that the sponsor does not support such use.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseNot accepted02 Sep 2026

The secretariat does not accept this submission. The Institute records what is supplied and what is used, because a reader encountering a compound outside a regulated route is the reader most in need of an assessment of the evidence for it.

The sections remain. Every such section already states the regulatory status of the use described and states that the evidence for it is assessed separately from the evidence for the approved indication. The submission is published in full and identified as an industry submission.

Dr Rurik Underhill-Okafor, PhD (Biostatistics) University department of medicinal chemistry
DRAFT-STABILITY-IN/004 received 11 Aug 2026

Rounding conventions are not stated and change the reported result

The respondent states that the draft reports figures to varying precision and does not specify when rounding occurs in the calculation chain, which can move a result across an acceptance limit.

The respondent proposes that rounding occur only at the reporting step and that the convention be stated.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted02 Sep 2026

The secretariat accepts this submission. Intermediate rounding is a silent source of disagreement between laboratories analysing the same material.

The standard now requires that no rounding be applied before the reporting step, states the reporting precision for each quantity, and states the rounding convention used at that step.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.